Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study

被引:9
|
作者
Meca-Lallana, Jose [1 ,2 ]
Ayuso, Teresa [3 ]
Martinez-Yelamos, Sergio [4 ]
Duran, Carmen [5 ]
Contreras Martin, Yessica [6 ]
Herrera Navarro, Nicolas [7 ]
Perez Sempere, Angel [8 ]
Alvarez-Cermeno, Jose C. [9 ]
Millan Pascual, Jorge [10 ]
Meca-Lallana, Virginia [11 ]
Romero Sevilla, Raul [12 ]
Ricart, Javier [12 ]
机构
[1] Hosp Clin Univ Virgen Arrixaca IMIB ARRIXACA, Serv Neurol, Unidad Esclerosis Multiple, Murcia, Spain
[2] Univ Catolica San Antonio, UCAM, Catedra Neuroinmunol Clin & Esclerosis Multiple, Murcia, Spain
[3] Hosp Navarra, Pamplona, Spain
[4] Hosp Bellvitge Princeps Espanya, Lhospitalet De Llobregat, Spain
[5] Hosp Univ Infanta Cristina, Badajoz, Spain
[6] Hosp Univ Nuestra Senora Candelaria, Santa Cruz De Tenerife, Spain
[7] Hosp Burgos, Burgos, Spain
[8] Hosp Gen Alicante, Alicante, Spain
[9] Hosp Univ Ramon y Cajal, IRYCIS, Madrid, Spain
[10] Complejo Hosp La Mancha Ctr, Alcazar De San Juan, Spain
[11] Hosp Univ Princesa, Unidad Enfermedades Desmielinizantes, Madrid, Spain
[12] Novartis Farmaceut SA, Barcelona, Spain
关键词
Multiple sclerosis; Second-line treatment; Effectiveness; Fingolimod; Natalizumab; PLACEBO-CONTROLLED TRIAL; OPTIONS;
D O I
10.1159/000505778
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: There is a lack of head-to-head studies comparing the efficacy of fingolimod (FIN) and natalizumab (NTZ) as second-line therapy for relapsing-remitting multiple sclerosis (RRMS). Methods: Multicenter, observational study, in which, information of 388 patients randomly selected and treated with FIN or NTZ in routine clinical practice was retrospectively collected with the main objective of comparing the annualized relapse rate (ARR) over the first year, after FIN or NTZ treatment initiation. Results: Mean ARR during the first year of treatment was 0.28 in FIN group and 0.12 in NTZ group (p = 0.0064); nevertheless, the difference between groups lost statistical significance when the propensity score analysis was performed. Time to disability -progression was similar in both treatment groups (12.3 +/- 6.7 months in FIN, and 12.8 +/- 0.1 months in NTZ; p = 0.4654). Treatment persistence after the first year of treatment was higher in patients treated with FIN (95%) than in those treated with NTZ (84%; p = 0.0014). Conclusions: After 12 months of treatment, both FIN and NTZ reduced the ARR, but ARR percent reduction was significantly higher with NTZ. Treatment persistence was higher in patients receiving FIN.
引用
收藏
页码:25 / 33
页数:9
相关论文
共 50 条
  • [21] Comparison of fingolimod versus interferon beta/glatiramer acetate as second-line therapy in active multiple sclerosis
    He, A.
    Spelman, T.
    Jokubaitis, V.
    Lugaresi, A.
    Izquierdo, G.
    Trojano, M.
    Grammond, P.
    Lechner-Scott, J.
    Duquette, P.
    Girard, M.
    Pucci, E.
    Slee, M.
    Grand'Maison, F.
    Oreja-Guevara, C.
    Boz, C.
    Fernandez-Bolanos, R.
    Hodgkinson, S.
    Sanchez-Menoyo, J.
    Iuliano, G.
    Barnett, M.
    Moore, F.
    Butzkueven, H.
    Kalincik, T.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 193 - 193
  • [22] Comparative effectiveness of natalizumab, fingolimod, and first-line therapies for rapidly evolving severe relapsing-remitting multiple sclerosis
    Spelman, T.
    Acosta, C.
    Hyde, R.
    Campbell, N.
    Havrdova, E.
    Horakova, D.
    Trojano, M.
    De Luca, G.
    Lugaresi, A.
    Izquierdo, G.
    Grammond, P.
    Duquette, P.
    Alroughani, R.
    Pucci, E.
    Granella, F.
    Lechner-Scott, J.
    Sola, P.
    Ferraro, D.
    Grand-Maison, F.
    Terzi, M.
    Rozsa, C.
    Boz, C.
    Hupperts, R.
    Van der Walt, A.
    Van Pesch, V.
    Oreja-Guevara, C.
    Jokubaitis, V.
    Kalincik, T.
    Butzkueven, H.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 526 - 527
  • [23] Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks
    Luciano Rinaldi
    P. Perini
    M. Calabrese
    P. Gallo
    Neurological Sciences, 2009, 30 : 171 - 173
  • [24] Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks
    Rinaldi, Luciano
    Perini, P.
    Calabrese, M.
    Gallo, P.
    NEUROLOGICAL SCIENCES, 2009, 30 : 171 - 173
  • [25] The Transition From First-Line to Second-Line Therapy in Multiple Sclerosis
    Jan Dörr
    Friedemann Paul
    Current Treatment Options in Neurology, 2015, 17
  • [26] The Transition From First-Line to Second-Line Therapy in Multiple Sclerosis
    Doerr, Jan
    Paul, Friedemann
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2015, 17 (06)
  • [27] Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
    Roos, Izanne
    Sharmin, Sifat
    Malpas, Charles
    Ozakbas, Serkan
    Lechner-Scott, Jeannette
    Hodgkinson, Suzanne
    Alroughani, Raed
    Izquierdo, Guillermo
    Eichau Madueno, Sara
    Boz, Cavit
    van der Walt, Anneke
    Butzkueven, Helmut
    Buzzard, Katherine
    Skibina, Olga
    Foschi, Matteo
    Grand'Maison, Francois
    John, Nevin
    Grammond, Pierre
    Terzi, Murat
    Prevost, Julie
    Barnett, Michael
    Laureys, Guy
    Van Hijfte, Liesbeth
    Luis Sanchez, Jose
    Blanco, Yolanda
    Oh, Jiwon
    Mccombe, Pamela
    Ramo Tello, Cristina
    Soysal, Aysun
    Prat, Alexandre
    Girard, Marc
    Duquette, Pierre
    Yamout, Bassem I.
    Khoury, Samia
    Van Pesch, Vincent
    Macdonell, Richard
    Sa, Maria Jose
    Slee, Mark
    Kuhle, Jens
    Maimone, Davide
    Spitaleri, Daniele L. A.
    Willekens, Barbara
    Al-Asmi, Abdullah
    Robertson, Neil
    Coles, Alasdair
    Brown, J. William L.
    Kalincik, Tomas
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 629 - 631
  • [28] Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis
    Sharmin, S.
    Lefort, M.
    Andersen, J.
    Horakova, D.
    Havrdova, E. K.
    Alroughani, R.
    Izquierdo, G.
    Eichau, S.
    Ozakbas, S.
    Butzkueven, H.
    Patti, F.
    Onofrj, M.
    Lugaresi, A.
    Terzi, M.
    Grammond, P.
    Grand'Maison, F.
    Yamout, B.
    Prat, A.
    Girard, M.
    Duquette, P.
    Boz, C.
    Trojano, M.
    McCombe, P.
    Slee, M.
    Lechner-Scott, J.
    Turkoglu, R.
    Sola, P.
    Ferraro, D.
    Granella, F.
    Shaygannejad, V.
    Prevost, J.
    Skibina, O.
    Solaro, C.
    Karabudak, R.
    Van Wijmeersch, B.
    Csepany, T.
    Spitaleri, D.
    Vucic, S.
    Leray, E.
    Sorensen, P. S.
    Sellebjerg, F.
    Magyari, M.
    Vukusic, S.
    Kalincik, T.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 786 - 788
  • [29] Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
    Roos, Izanne
    Sharmin, Sifat
    Malpas, Charles
    Ozakbas, Serkan
    Lechner-Scott, Jeannette
    Hodgkinson, Suzanne
    Alroughani, Raed
    Eichau Madueno, Sara
    Boz, Cavit
    van der Walt, Anneke
    Butzkueven, Helmut
    Buzzard, Katherine
    Skibina, Olga
    Foschi, Matteo
    Grand'Maison, Francois
    John, Nevin
    Grammond, Pierre
    Terzi, Murat
    Prevost, Julie
    Barnett, Michael
    Laureys, Guy
    Van Hijfte, Liesbeth
    Luis Sanchez-Menoyo, Jose
    Blanco, Yolanda
    Oh, Jiwon
    Mccombe, Pamela
    Ramo Tello, Cristina
    Soysal, Aysun
    Prat, Alexandre
    Duquette, Pierre
    Yamout, Bassem, I
    Khoury, Samia
    van Pesch, Vincent
    Macdonell, Richard
    Jose Sa, Maria
    Slee, Mark
    Kuhle, Jens
    Maimone, Davide
    Spitaleri, Daniele L. A.
    Willekens, Barbara
    Asmi, Abdallah Al
    Tallantyre, Emma
    Robertson, Neil P.
    Coles, Alasdair
    Brown, J. William
    Kalincik, Tomas
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (09) : 1163 - 1175
  • [30] Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries
    Putzki, N.
    Yaldizli, O.
    Maeurer, M.
    Cursiefen, S.
    Kuckert, S.
    Klawe, C.
    Maschke, M.
    Tettenborn, B.
    Limmroth, V.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 (01) : 31 - 37